Genome damage is a hallmark of human cancer. Efforts at assessing the impact of genome damage on tumor phenotype and patients outcome have focused on measurements of the relative DNA content in tumor cells compared to normal cells and the assessment of allelic loss at single or multiple selected loci that are thought to harbor genes important in cancer biology. We adapted a global, high-resolution genotyping method for determination of global and unbiased allelic loss. We generated a score, termed global genome damage score (GGDS), that is a continuous variable from zero to one and a measure of the extent of damaged DNA in individual tumors. In 71 patients with completely resected non-small-cell lung cancer, the GGDS ranged from 0.0006 to 0.5530 with a median value of 0.0401 indicating that between 0.06 and 55.3% of the genome has allelic loss. Patients with high scores (>0.04) had a significantly worse outcome than those with low scores (median overall survival time 35.5 vs >120.0 months, P ¼ 0.006 log-rank test; median diseasefree survival 28.3 vs >120.0 months, P ¼ 0.003 log-rank test). This suggests that the clinical behavior of lung tumors with low GGDS is relatively benign whereas tumors with high GGDS are aggressive resulting in early death of patients.
Genome damage is a hallmark of human cancer. Efforts at assessing the impact of genome damage on tumor phenotype and patients outcome have focused on measurements of the relative DNA content in tumor cells compared to normal cells and the assessment of allelic loss at single or multiple selected loci that are thought to harbor genes important in cancer biology. We adapted a global, high-resolution genotyping method for determination of global and unbiased allelic loss. We generated a score, termed global genome damage score (GGDS) , that is a continuous variable from zero to one and a measure of the extent of damaged DNA in individual tumors. In 71 patients with completely resected non-small-cell lung cancer, the GGDS ranged from 0.0006 to 0.5530 with a median value of 0.0401 indicating that between 0.06 and 55.3% of the genome has allelic loss. Patients with high scores (>0.04) had a significantly worse outcome than those with low scores (median overall survival time 35.5 vs >120.0 months, P ¼ 0.006 log-rank test; median diseasefree survival 28.3 vs >120.0 months, P ¼ 0.003 log-rank test). This suggests that the clinical behavior of lung tumors with low GGDS is relatively benign whereas tumors with high GGDS are aggressive resulting in early death of patients. Oncogene (2006 Oncogene ( ) 25, 4491-4494. doi:10.1038 published online 6 March 2006 Keywords: lung cancer; chromosome aberrations; prognosis; survival Damage of genomic DNA derived from human tumors as assessed by molecular, cellular or cytogenetic methods is a hallmark of human malignancies (Yunis, 1983) . This damage appears to result from increased chromosome fragility and/or impaired repair of DNA strand breaks during cell cycle progression (Hoeijmakers, 2001) . On a chromosomal level, various aberrations are observed that can lead to complete or partial loss or altered function of genes important for the maintenance of a normal cellular phenotype and thus can contribute to tumor promotion (Fearon and Vogelstein, 1990) . Other types of genome damage with biological consequences include gene mutations and altered transcription through mutations or epigenetic modifications in regulatory elements (Vogelstein et al., 1988) . Examples for each of these mechanisms are plentiful in the literature.
Loss of DNA through genomic aberrations at specific loci can be detected in tumor DNA if the region involved contains polymorphic sites, that is, loss of heterozygosity (LOH) (Cavenee et al., 1983) . Polymorphisms include simple nucleotide repeat polymorphisms (Bell et al., 1982; Jeffreys et al., 1985; Nakamura et al., 1987) and single nucleotide polymorphisms (SNPs) (Botstein et al., 1980) . Single nucleotide polymorphisms can be detected by restriction fragment length analysis or by using oligonucleotides as probes that specifically detect target DNA based on single nucleotide variations.
Loss of heterozygosity determination as a method for assessment of genome damage at single or several specific chromosomal loci that harbor genes important in tumor biology has been explored as a marker of tumor phenotype, ranging from tissue-specific patterns (molecular diagnostics), to early diagnosis (molecular screening), to tumor behavior (prediction of survival and response to therapy). For instance, we had found that LOH at chromosome segment 11p15.5 is correlated with metastatic spread of non-small-cell lung cancer (NSCLC) and poor outcome of patients with this disease (Bepler et al., 2002) . Other examples include LOH at 3p and 5q in lung cancer (Fong et al., 1995; Mitsudomi et al., 1996) , 18q in colon cancer (Jen et al., 1994) and 11p in breast cancer (Ali et al., 1987) . The average number of loci with LOH on a genome-wide scan is unknown, but there is reason to believe that it is between 5 and 50% (Vogelstein et al., 1989) .
To assess if global genome damage impacts on tumor phenotype, we adapted a genome-wide high-throughput genotyping method that is based on match/mismatch hybridization of amplified genomic DNA to SNP-specific oligonucleotides for global genome damage assessment (GeneChip Mapping 10K Array, Affymetrix, Santa Clara, CA, USA). The 11 560 SNPs on the array had been selected based on genomic distribution, HardyWeinberg equilibrium and informativeness (median heterozygosity 36%, 25th percentile 22% and 75th percentile 47%). A total of 250 ng DNA is required to obtain reliable signals. The method has an average genotyping reproducibility of 99.65% when compared to standard techniques. DNA amplification and array hybridization were performed as specified by the manufacturer. Hybridization signals were captured with a GCS 3000 scanner (Affymetrix), and data were analyzed using GeneChip DNA analysis software, version 2.0 (Affymetrix).
We had prospectively collected primary tumors and matched normal lung specimens from 71 patients who underwent complete surgical resection for NSCLC. Of these, 36 were adenocarcinomas, 32 were squamous cell carcinomas and three were large cell carcinomas. None of these patients had received radiation or chemotherapy as neoadjuvant or adjuvant treatment. Tumor specimens and corresponding normal lung were snap frozen in liquid nitrogen after surgical resection and macroscopic inspection by an anatomical pathologist. The time elapsed from resection to freezing was recorded, and it was 20 min or less for all specimens. All specimens were microscopically reviewed to confirm tissue diagnosis and for selection of areas with high tumor cell content for microdissection by scalpel. The content of tumor cells compared to the total number of cells in the samples was estimated to exceed 60%. Normal lung was selected from an area in the same lobe of the lung as the tumor but clearly distant and noncontiguous from it. Genomic DNA from these specimens was extracted, quantified and assessed for integrity by standard techniques.
We anticipated obtaining information on the absence or presence of genome damage for B4150 loci for each patient based on the median heterozygosity rate of 36% for all markers on the chip. In the 71 normal DNA samples, we achieved a median call rate of 94.23% (range 73.18-98.09%), thus giving us a median of 3921 (33.9%) heterozygous loci (range 1886-4033; 20.9-35.8%). This was within the expected range, and it is equivalent to one informative locus every 821 000 bp (range 744 000-1 591 000 bp) on the entire human genome.
For determination of global and unbiased genome damage, we generated a global genome damage score (GGDS), which is a measure of the extent of damaged DNA in individual tumors. For each of the heterozygous loci in normal DNA from 71 patients, the allele signal in the corresponding tumor DNA was analysed with 11 different algorithms to determine whether or not allele loss was present or absent. We calculated the GGDS by dividing the number of loci with evidence for allele loss by the total number of informative loci. The algorithms were as follows: (1) A locus was determined to have allele loss if it was heterozygous in the normal specimen and if the allele call in the tumor was homozygous. (2) A locus was determined to have allele loss if it was heterozygous in the normal specimen and if the DRAS in the tumor specimen was >0.5 regardless of the allele call in the tumor. DRAS is the difference in the relative allele signal intensities between normal and tumor specimens. (3) Same as (2) but DRAS>0.4. (4) Same as (2) but DRAS>0.354, which is equivalent to a signal intensity reduction of 50% on traditional gel analysis. (5) Same as (2) but DRAS>0.3. (6) Same as (2) but DRAS>0.2. (7) A locus was determined to have . Initial graphical explorations were performed to examine the reasonableness of the proportional hazards assumption for the relationship of GGDS with OS and DFS. Because that assumption seemed questionable, the analyses of the effect of GGDS on OS and DFS were based on log-rank test with the sample dichotomized using GGDS cutpoints instead of proportional hazards regression. As a first step, the median value of GGDS was found and log-rank tests used to compare those equal to or higher than the median to those lower than the median with respect to OS and DFS. Similar comparisons were made for quartiles. In addition, multiple log-rank tests were used to find an optimal cutpoint that would best distinguish poor from good outcome patients. The associated P-values were corrected for multiple looks (Contal and O'Quigley, 1999; Mandrekar, 2003) . In order to present the effects of GGDS graphically, we dichotomized GGDS as above or below the median and produced Kaplan-Meier graphs of the estimated survival and DFS functions for high-and low-GGDS subsets. Version 9.1.3 of SAS R statistical software (Procs Lifetest, Corr, Means, and Nonpar1way) was used for all calculations.
Global genome damage score and lung cancer Z Zheng et al allele loss if it was heterozygous in the normal specimen, the locus had a formal allele call in the tumor and if the DRAS in the tumor specimen was >0.5. (8) Same as (7) but DRAS>0.4. (9) Same as (7) but DRAS> 0.354, which is equivalent to a signal intensity reduction of 50% on traditional gel analysis. (10) Same as (7) but DRAS>0.3. (11) Same as (7) but DRAS>0.2. Using these 11 algorithms, GGDS values were highly correlated (Po0.0001 for Spearman correlation coefficients, most coefficients >0.50) (Table 1) . Therefore, we used algorithm 4 for subsequent investigations, as it is approximately equivalent to a 50% reduction in allele signal intensities in traditional gel analyses. With this approach, the GGDS ranged from 0.0006 to 0.5530 with a median of 0.0401 indicating that 0.06-55.3% of the entire genome is damaged in lung tumors.
We assessed if GGDS would be predictive of overall and disease-free survival (OS and DFS) and demographic and epidemiologic characteristics in these 71 patients. Data collection was approved by the Institutional Review Board. Overall survival was the time elapsed from diagnosis to death. Disease-free survival was the time elapsed from surgical resection to disease recurrence or death. All patients were monitored with physical exam and chest radiographs or computed tomography at regular intervals ranging from 3 to 12 months.
When the cohort was dichotomized into high (>0.04) versus low (o0.04) GGDS based on the cohort median (0.0401), OS and DFS were significantly different (OS, P ¼ 0.006, N ¼ 71; DFS, P ¼ 0.003, N ¼ 69). Patients with low GGDS lived longer and had disease recurrence later than those with high GGDS (Figure 1a and b) .
A proportional hazards regression produced significant hazard ratios for OS (HR ¼ 2.52, P ¼ 0.005) and DFS (HR ¼ 2.70, P ¼ 0.003) when comparing high with low GGDS. When dividing the cohort into quartiles, there were significant (P ¼ 0.02) differences between the groups with respect to both OS and DFS (group 1: 0.0006-0.0078, N ¼ 18; group 2: 0.0078-0.0395, N ¼ 17; group 3: 0.0401-0.0789, N ¼ 18; group 4: 0.0804-0.5530, N ¼ 18) (Figure 2 ). In fact, nine patients (50%) in group 1 and 11 (65%) in group 2 were alive at the time of analysis compared to four patients (22%) in group 3 and five (28%) in group 4. Overall survival and DFS did not differ significantly between groups 1 and 2 or groups 3 and 4. However, they differed significantly between c Active smokers were patients who had not quit smoking or claimed to have quit for less than 1 year before diagnosis; former smokers were patients who had quit for more than 1 year; and never smokers were patients with a lifetime consumption of less than 100 cigarettes.
d Kuskal-Wallis test. The reported P-values are based on the asymptotic normal distribution of the test statistic. Non-parametric statistical tests were chosen because GGDS values did not appear to be normally distributed as confirmed by a highly significant Shapiro-Wilk test. All P-values reported are two-sided.
e Tumor staging was performed according to the 2002 American Joint Committee on Cancer staging criteria, and it was based on radiographic and surgical evaluations (pathological staging). Stage III/IV encompassed seven patients with stage IIIA, two with IIIB (both had T4 disease as a result of a second tumor nodule in the same lobe of the lung as the primary lung cancer; one had N0 and the other N1 lymph node involvement) and two with stage IV disease (both had stage IV disease as a result of a second tumor nodule in a different lobe of the lung as the primary cancer; both had no evidence for lymph node involvement or other distant metastatic disease). groups 2 and 3 (OS, P ¼ 0.013; DFS, P ¼ 0.008). Looking at all possible cut points for cohort dichotomization and keeping group sizes above 10, the optimal cut point for OS was achieved using a GGDS of 0.0395. Using this cut point, 34 patients had low (0.0006-0.0338) and 37 had high GGDS (0.0401-0.5530) with a P-value of 0.006 for OS, which was the same as for cohort dichotomization using the median. These data strongly suggest that there is a threshold effect for GGDS.
In this group of patients, GGDS was not significantly associated with patients' age, gender, cigarette use, tumor stage, tumor histology, performance status or weight loss (Table 2 ). Multivariate analysis of OS and DFS using GGDS, age, pathologic stage, gender and smoking history yielded similar results for the effect of GGDS adjusting for the other variables, none of which significantly impacted OS and DFS. The adjusted hazard ratios were 3.08 (P ¼ 0.002) for OS and 3.3 (P ¼ 0.001) for DFS.
To date, genome-wide allele loss analysis could be performed using simple nucleotide repeat polymorphisms such as di-, tri-and tetra-nucleotide repeats. A well-characterized set of such polymorphisms contains 201 loci with a median heterozygosity rate of 74% thus providing information on 149 loci (Research Genetics, Version 10A). In addition, simple nucleotide repeat polymorphisms are not randomly distributed in the genome as some are clustered near telomeres (Royle et al., 1988) . Thus, the SNP array analysis allows for an approximately 25-fold higher resolution and more even distribution of loci on genome-wide allele loss analysis as an indicator of global genome damage.
Previous attempts at assessing the impact of global genome damage on tumor phenotype included the measurement of the relative tumor cell DNA content compared to normal diploid cells (DNA index). Several reports have suggested that a non-diploid DNA index is associated with poor outcome of cancer patients (Barlogie et al., 1982; Wolley et al., 1982; Auer et al., 1984; Volm et al., 1985) . Allelotyping of 56 colorectal carcinomas at a single selected locus for each of the 46 non-acrocentric chromosome arms had revealed a median allelic deletion of 20%, and patients whose tumors had greater than 20% of allelic deletions had a shorter survival than those with less than 20% (Vogelstein et al., 1989) . However, a global, highresolution and unbiased assessment of genome damage through allelotyping and its impact on the in vivo behavior of human epithelial malignancies had not been performed.
Our study of global high-resolution genome damage analysis in a human epithelial malignancy convincingly demonstrates a statistically significant and clinically meaningful association with the in vivo tumor phenotype. This implies that the clinical behavior of tumors with low GGDS is relatively benign, whereas tumors with high GGDS are aggressive resulting in early death of patients. The statistical data analysis strongly suggests that there is a threshold effect for GGDS and that a cut-point of 0.04 divides patients into high-and low-risk groups. As GGDS determination is a robust and reliable technology, it can easily be integrated into clinical decisions on cancer care. For instance, adjuvant treatment of epithelial malignancies benefits only a minority of patients although toxicity is substantial. GGDS may prove useful in selecting patients at high risk for tumor-associated mortality for adjuvant therapeutic interventions. However, it is imperative to test this hypothesis in well-designed prospective clinical trials to corroborate our results before implementation in disease management.
